Tina Vilsbøll

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Mansoor Husain, Andreas L. Birkenfeld, Morten Donsmark et al. · New England Journal of Medicine · 2019 · 1.9K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients

Tina Vilsbøll, Thure Krarup, Carolyn F. Deacon et al. · Diabetes · 2001 · 884 citations · Full text

Medicine, Endocrinology, Nutrition +16

Recovery of gut microbiota of healthy adults following antibiotic exposure

Albert Pallejá, Sofia K. Forslund, Alireza Kashani et al. · Nature Microbiology · 2018 · 873 citations

Life Sciences, Immunology, Microbiology +15

Incretin Secretion in Relation to Meal Size and Body Weight in Healthy Subjects and People with Type 1 and Type 2 Diabetes Mellitus

Tina Vilsbøll, Thure Krarup, Jesper Sonne et al. · The Journal of Clinical Endocrinology & Metabolism · 2003 · 523 citations

Life Sciences, Endocrinology, Physiology +17

Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes

Tina Vilsbøll, Milan Zdravkovic, T Le-Thi et al. · Diabetes Care · 2007 · 471 citations · Full text

Medicine, Endocrinology, Pharmacology +11